Table IV.
Proto-oncogene B-Raf (BRAF) variants in lung adenocarcinomas and immunohistochemical positivity for programmed death-ligand 1 (PD-L1) in lung squamous cell carcinomas. Each variant is characterized by specific amino acid substitution at a given position in the protein, the specific DNA exon region, its pathogenicity, and the actual number represented in each cohort (n). Standard one letter codes indicate mutation-induced changes in amino acids.
| Gene/variant | Exon | Function | AA (n) | CC (n) | p-Value |
|---|---|---|---|---|---|
| BRAF | 0.020‡ | ||||
| Total assayed | 51 | 108 | |||
| G469A | 11 | P | 1 | 2 | |
| D594N | 15 | PP | 2 | 0 | |
| G596R | 15 | P | 0 | 1 | |
| K601E | 15 | PP | 1 | 0 | |
| V600E | 15 | P | 3 | 1 | |
| Immunohistochemical positivity | AA | CC | p-Value | ||
| PD-L1 | |||||
| Total assayed, n | 11 | 20 | 0.022‡ | ||
| Positively stained, n | 0 | 7 | |||
| Percentage | 0.0 | 35.0 | |||
AA, African Americans; CC, Caucasians; P, pathogenic; PP, presumed pathogenic.
‡
Chi-square test.